DOI:
10.1055/s-00000020
Geburtshilfe und Frauenheilkunde
LinksClose Window
References
Pivot XB, Bondarenko I, Dvorkin M. et al.
A randomized, double-blind, phase III study comparing SB3 (trastuzumab biosimilar) with originator trastuzumab in patients treated by neoadjuvant therapy for HER2-positive early breast cancer.
J Clin Oncol 2017;
35 (Suppl.) Abstr. 509
Search in:
We do not assume any responsibility for the contents of the web pages of other providers.